Kerry Breen is a news editor at CBSNews.com. A graduate of New York University's Arthur L. Carter School of Journalism, she previously worked at NBC News' TODAY Digital. She covers current events, ...

Lines of fans spanning generations gathered at Chain Reaction’s tiny strip mall parking lot for the venue’s final show. Chain Reaction hosted its last event on Friday, Dec. 19, featuring Rancho Santa ...

Welcome back to The Conversation, where Newsweek highlights reader comments from the past week. We turn our focus this week to President Donald Trump, who on Wednesday night delivered a year-end ...

Anaheim’s all-ages club Chain Reaction announced that it will officially close its doors this month. “For almost 30 years, Chain Reaction has proudly fostered the alt-music scene by creating a space ...

"We designed the volumes so they’re basically like mega movies. The end of episode four has its own climax and I’m excited how they react to that," Matt Duffer previously told The Hollywood Reporter.

The National Guard is developing a “quick reaction force” of troops trained in crowd control and civil disturbance that can be ready to deploy to U.S. cities by January, according to a leaked memo ...

Helen E Nuttall receives funding from UKRI, the Vivensa Foundation, North West Cancer Research, and Rosemere Cancer Foundation. Hearing involves more than just the ears – it’s intimately connected to ...

Complement 3 glomerulopathy (C3G) is a rare kidney disease that affects your body’s innate immune system (complement system). Complement 3 glomerulopathy (C3G) is a kidney disease that’s caused by ...

Dipa Kamdar does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their ...

In the heated debates over trade policy in Washington and beyond, tariffs are often portrayed as the primary—or even the sole—instrument by which governments intervene in global commerce. They are ...

Centauri plans the progression of lead candidate, an immunotherapy based broad-spectrum antimicrobial, to a first in human clinical study in early 2026 CARB-X’s additional funding brings their ...

Centauri Therapeutics Limited ('Centauri'), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, announced today that ...